Background: The aim of the present study was to evaluate MRI response rate and clinical outcome of short-course radiotherapy (SCRT) on rectal cancer as an alternative to chemoradiotherapy in patients where downstaging is indicated.
Methods: A retrospective analysis was performed of a patient cohort with rectal carcinoma (cT1-4cN0-2 cM0-1) from a large teaching hospital receiving restaging MRI, deferred surgery or no surgery after SCRT between 2011 and 2017. Patients who received chemotherapy during the interval between SCRT and restaging MRI were excluded. The primary outcome measure was the magnetic resonance tumor regression grade (mrTRG) at restaging MRI after SCRT followed by a long interval. Secondary, pathological tumor stage, complete resection rate and 1-year overall survival were assessed.
Results: A total of 47 patients (M:F = 27:20, median age 80 (range 53-88) years), were included. In 33 patients MRI was performed for response assessment 10 weeks after SCRT. A moderate or good response (mrTRG≤3) was observed in 24 of 33 patients (73%). While most patients (85%; n = 28) showed cT3 or cT4 stage on baseline MRI, a ypT3 or ypT4 stage was found in only 20 patients (61%) after SCRT (p < 0.01). A complete radiologic response (mrTRG 1) was seen in 4 patients (12%). Clinical N+ stage was diagnosed in n = 23 (70%) before SCRT compared to n = 8 (30%) post-treatment (p = 0.03). After SCRT, 39 patients underwent deferred surgery (after a median of 14 weeks after start of SCRT) and a resection with complete margins was achieved in 35 (90%) patients. One-year overall survival after surgery was 82%. Complete pathological response was found in 2 patients (5%).
Conclusions: The use of SCRT followed by a long interval to restaging showed a moderate to good response in 73% and therefore can be considered as an alternative to chemoradiotherapy in elderly comorbid patients.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7053128 | PMC |
http://dx.doi.org/10.1186/s13014-020-01500-y | DOI Listing |
Int J Colorectal Dis
January 2025
General Surgery Department, HM Sanchinarro University Hospital, Madrid, Spain.
Introduction: Accurate identification of patients with pathologic complete response (pCR) following neoadjuvant radiochemotherapy (RCT) for locally advanced rectal cancer (LARC) is essential. 18-FDG PET/MRI provides metabolic information that complements the morphological assessment of standard MRI, potentially enhancing the differentiation between fibrotic and tumorous tissues post-treatment. This study aims to evaluate the performance of 18-FDG PET/MRI in assessing treatment response compared to standard MRI.
View Article and Find Full Text PDFAbdom Radiol (NY)
December 2024
Faculty of Medicine, Alexandria University, Alexandria, Egypt.
Urinary bladder cancer is a global disease that poses medical and socioeconomic challenges to patients and healthcare systems. Predicting detrusor invasiveness and pathological grade of bladder cancer by the radiologist is imperative for informed decision-making and effective patient-tailored therapy. Cystoscopy and TURBT are the current gold standard for preoperative histologic diagnosis and local pathological staging but are compromised by their intrusiveness, under-sampling, and staging inaccuracies.
View Article and Find Full Text PDFEur J Radiol
December 2024
Department of Internal Medicine, Pathum Thani Hospital, 7 Ladlumkaew Muang district, Pathum Thani 12000, Thailand.
Bladder cancer is categorized into nonmuscle-invasive bladder cancer (NMIBC) and muscle-invasive bladder cancer (MIBC), distinguished by the presence of detrusor muscle invasion. Urothelial cell carcinoma is the most common subtype of bladder cancer. Transurethral resection of bladder tumor (TURBT) is the standard approach for staging and managing NMIBC, while radical cystectomy remains the cornerstone treatment for MIBC.
View Article and Find Full Text PDFDiagnostics (Basel)
November 2024
Department of Radiology, Adana City Training and Research Hospital, University of Health Sciences, Adana 01230, Turkey.
Ann Nucl Med
November 2024
Department of Nuclear Medicine, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Hualien, 970423, Taiwan.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!